IMULAN’s Atopic Dermatitis and Stomatitis Technology Awarded Composition of Matter Patent Prescott, AZ. – (January 24th, 2012)   Imulan BioTherapeutics, LLC (IMULAN) has strengthened their intellectual property position from a recently awarded composition of matter patent.  The patent was issued on IMULAN’s licensed T-cell receptor (TCR) peptide therapeutics, which are classified as immuno-biologics.  IMULAN holds the [...]

Prescott, AZ. – (August 3rd, 2011)   Imulan BioTherapeutics, LLC (IMULAN) announced they have received a grant from the American Kennel Club entitled, “Placebo-controlled trial of T-cell receptor (TCR) peptide treatment in dogs with non-responsive atopic dermatitis”.  IMULAN’s T-Cell Receptor (TCR) peptide vaccine has previously shown significant benefits in blinded, placebo controlled studies in dogs with [...]

Prescott, AZ. – (January 12th, 2011)   Imulan BioTherapeutics, LLC (IMULAN) has identified a new biomarker for atopic dermatitis.  Using dogs as the atopic model, IMULAN found a highly significant (p<0.001) increase in expression of the biomarker in atopic dermatitis subjects compared to normal subjects.  IMULAN’s Enzyme Linked Immunosorbent Assay (ELISA) found a 16-fold increase in [...]

IMULAN’s Stomatitis Immunotherapeutic Shows Promise St. Joseph, MO. – (June 22nd, 2010)   Imulan BioTherapeutics, LLC (IMULAN) announced encouraging early results from clinical trials on their T-Cell Receptor (TCR) therapeutic vaccine for feline stomatitis.  Feline stomatitis, also referred to as gingivostomatitis, is an immune mediated inflammatory condition affecting the oral cavity.  The TCR therapeutic vaccine is [...]

April 01, 2010 – IMULAN BioTherapeutics’ new product leukoSTAT, is the first veterinary nutritional product containing the Immune Selective Anti-Inflammatory Derivatives (ImSAID ). This new technology uses naturally occurring amino acid complexes which evolved to regulate leukocytes, the source of all inflammatory processes. These specific amino acid sequences in leukoSTAT have been shown in numerous [...]

(November 12, 2009) – Imulan BioTherapeutics, LLC (IMULAN) announced the release of LeukoSTAT™; a nutritional product containing a newly recognized class of naturally occurring amino acid complexes referred to as ImSAIDs (Immune Selective Anti-Inflammatory Derivatives). Originally discovered as important components of saliva, ImSAIDS have been shown to target leukocytes, thereby going right to the source [...]

St. Joseph, MO. – (October 21st, 2009)   Imulan BioTherapeutics, LLC (IMULAN) has been selected to present their most recent findings on feline stomatitis at this year’s Veterinary Dental Forum.  The session entitled “T-Cell Receptor Peptide Technology for Feline Stomatitis” will be presented by Dr. Craig Woods.  The T-Cell Receptor (TCR) technology, a biologic immune modulator, [...]

IMULAN BioTherapeutics, LLC announced they are prepared to commence with regulated trials to complete work on the T-Cell Receptor peptide immunomodulator, for atopic dermatitis in dogs. Canine atopic dermatitis is a very prevalent condition in dogs, thought to affect up to 5 percent of the dog population. Clinical signs of atopic dermatitis include pruritus (itching) [...]

St. Joseph, MO. – (May 12th, 2009) Imulan BioTherapeutics, LLC (IMULAN) announced encouraging echocardiographic findings from a recent pilot trial using their T-Cell Receptor (TCR) peptides for canine dilated cardiomyopathy. The study was supported by a grant from the American Kennel Club Canine Health Foundation and conducted by veterinary cardiologists in dogs with stable but [...]

Prescott, AZ and St. Joseph, MO. – (April 1, 2009) Imulan BioTherapeutics, LLC (IMULAN) announced they received a grant from the American Kennel Club Canine Health Foundation entitled “Development of a Diagnostic Method for Canine Atopic Dermatitis”. This grant is based on IMULAN’s T-Cell Receptor (TCR) peptide technology platform, the same platform being used to [...]